- Home
- DC vs CTMX Comparison
DC vs CTMX Comparison
Compare DC & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DC | CTMX |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 620.7M | 596.2M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | DC | CTMX |
|---|---|---|
| Price | $5.59 | $4.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $9.38 | $6.50 |
| AVG Volume (30 Days) | 1.1M | ★ 2.8M |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.22 |
| EPS | N/A | ★ 0.24 |
| Revenue | N/A | ★ $113,631,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $17.20 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.21 | $0.40 |
| 52 Week High | $6.25 | $4.66 |
Technical Indicators
Market Signals| Indicator | DC | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 52.87 | 51.55 |
| Support Level | $5.32 | $3.98 |
| Resistance Level | $6.25 | $4.66 |
| Average True Range (ATR) | 0.24 | 0.28 |
| MACD | -0.10 | -0.02 |
| Stochastic Oscillator | 25.27 | 34.16 |
Price Performance
Historical ComparisonAbout DC Dakota Gold Corp.
Dakota Gold Corp is a gold exploration and development company with a specific focus on revitalizing the Homestake District in Lead, South Dakota. Dakota Gold has high-caliber gold mineral properties covering over 48 thousand acres surrounding the historic Homestake Mine. Company project includes Richmond Hill Project.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.